Target Information

Target General Information

Top

Target ID

T99799 (Former ID: TTDS00143)

Target Name

Cholinesterase (BCHE)

Synonyms

Pseudocholinesterase; Choline esterase II; CHE1; Butyrylcholine esterase; Acylcholine acylhydrolase

Click to Show/Hide

Gene Name

BCHE

Target Type

Successful target

[1]

Disease

[+] 2 Target-related Diseases

Pain [ICD-11: MG30-MG3Z]

Tonus and reflex abnormality [ICD-11: MB47]

Function

Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.

Click to Show/Hide

BioChemical Class

Type-B carboxylesterase/lipase

UniProt ID

CHLE_HUMAN

EC Number

EC 3.1.1.8

Sequence

MHSKVTIICIRFLFWFLLLCMLIGKSHTEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIP
YAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDC
LYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALG
FLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPG
SHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEI
LLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVY
GAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDV
VGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLER
RDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMT
KLRAQQCRFWTSFFPKVLEMTGNIDEAEWEWKAGFHRWNNYMMDWKNQFNDYTSKKESCV
GL

Click to Show/Hide

3D Structure

Click to Show 3D Structure of This Target

PDB

ADReCS ID

BADD_A00300 ; BADD_A00362 ; BADD_A01261 ; BADD_A01322 ; BADD_A02053 ; BADD_A04623

HIT2.0 ID

T25Y64

Drugs and Modes of Action

Top

Approved Drug(s)

[+] 2 Approved Drugs

Hexafluronium bromide

Drug Info

Approved

Spasm

[2], [3]

MEPTAZINOL

Drug Info

Approved

Pain

[2]

Clinical Trial Drug(s)

[+] 6 Clinical Trial Drugs

(-)-Phenserine

Drug Info

Phase 3

Alzheimer disease

[4]

Eptastigmine

Drug Info

Phase 3

Cognitive impairment

[5]

JES-9501

Drug Info

Phase 1

Alzheimer disease

[6]

Plasma derived human butyrylcholinesterase

Drug Info

Phase 1

Neurotoxicity

[7]

Protexia

Drug Info

Phase 1

Alzheimer disease

[8]

RVT-103+RVT-104

Drug Info

Phase 1

Alzheimer disease

[9]

Mode of Action

[+] 2 Modes of Action

Inhibitor

[+] 196 Inhibitor drugs

Hexafluronium bromide

Drug Info

[1]

MEPTAZINOL

Drug Info

[10]

(-)-Phenserine

Drug Info

[11]

Eptastigmine

Drug Info

[12]

RVT-103+RVT-104

Drug Info

[9]

Di-substituted piperidine derivative 1

Drug Info

[15]

Di-substituted piperidine derivative 2

Drug Info

[15]

Di-substituted piperidine derivative 3

Drug Info

[15]

Egonol compound 1

Drug Info

[16]

Indoline derivative 1

Drug Info

[15]

Isochroman-4-ketone derivative 1

Drug Info

[15]

PMID29757691-Compound-2a

Drug Info

[15]

PMID29757691-Compound-8a

Drug Info

[15]

PMID29757691-Compound-8b

Drug Info

[15]

PMID29757691-Compound-8d

Drug Info

[15]

Quinazoline alkaloid derivative 1

Drug Info

[15]

Tacrine heterodimer derivative 1

Drug Info

[15]

Tetra-hydro-isoquinoline derivative 1

Drug Info

[15]

Tetra-hydro-isoquinoline derivative 2

Drug Info

[15]

Tetra-hydro-isoquinoline derivative 3

Drug Info

[15]

Tetra-hydro-isoquinoline derivative 4

Drug Info

[15]

(-)-DEBROMOFLUSTRAMINE B

Drug Info

[17]

(-)-Tolserine

Drug Info

[11]

(1'H-Phenothiazin-1'-yl)(piperidin-1-yl)methanone

Drug Info

[18]

(10H-phenothiazin-10-yl)(m-tolyl)methanone

Drug Info

[19]

(10H-phenothiazin-10-yl)(o-tolyl)methanone

Drug Info

[19]

(10H-phenothiazin-10-yl)(p-tolyl)methanone

Drug Info

[19]

(10H-phenothiazin-10-yl)(phenyl)methanone

Drug Info

[19]

(1R)-MENTHYL HEXYL PHOSPHONATE GROUP

Drug Info

[20]

(1S)-MENTHYL HEXYL PHOSPHONATE GROUP

Drug Info

[20]

(24S)-ethylcholesta-7,9(11),22(E)-triene-3b-ol

Drug Info

[21]

(3-bromophenyl)(10H-phenothiazin-10-yl)methanone

Drug Info

[19]

(4-bromophenyl)(10H-phenothiazin-10-yl)methanone

Drug Info

[19]

(RS)-tacrine(10)-hupyridone

Drug Info

[22]

1,11-bis(pyridinium)-undecane dibromide

Drug Info

[23]

1,2-bis(2,3-fluorophenyl)ethane-1,2-dione

Drug Info

[24]

1,2-di(10H-phenothiazin-10-yl)ethane-1,2-dione

Drug Info

[19]

1,2-Di(berberine-9-O-yl)ethane dibromide

Drug Info

[25]

1,2-indanedione

Drug Info

[26]

1,3-Di(berberine-9-O-yl)ethane dibromide

Drug Info

[25]

1,4-Di(berberine-9-O-yl)ethane dibromide

Drug Info

[25]

1,9-bis(pyridinium)-nonane dibromide

Drug Info

[23]

1-(10H-phenothiazin-10-yl)-2-phenylbutan-1-one

Drug Info

[19]

1-(10H-phenothiazin-10-yl)-2-phenylethanone

Drug Info

[19]

1-(10H-phenothiazin-10-yl)-2-phenylpropan-1-one

Drug Info

[19]

1-(10H-phenothiazin-10-yl)-3-phenylbutan-1-one

Drug Info

[19]

1-(10H-phenothiazin-10-yl)-3-phenylpropan-1-one

Drug Info

[19]

1-(3,4-dichlorobenzyl)-1H-indole-2,3-dione

Drug Info

[27]

1-methyl-3-(phenylcarbamoyloxy)pyridinium bromide

Drug Info

[11]

2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)-imine

Drug Info

[28]

2-(N-Morpholino)-Ethanesulfonic Acid

Drug Info

[29]

2-biphenyl-4-yl-1-phenothiazin-10-yl-ethanone

Drug Info

[19]

2-methoxyphenyl 10H-phenothiazine-10-carboxylate

Drug Info

[30]

2-Methyl-beta-carboline-2-ium iodide

Drug Info

[31]

2-Propyl-beta-carboline-2-ium iodide

Drug Info

[31]

24-ethyl-cholest-7-ene-3,5,6-triol

Drug Info

[21]

3,4,5,6-Tetrachloro-[1,2]benzoquinone

Drug Info

[32]

3-(2-Diethylamino-acetamino)-rutaecarpine

Drug Info

[33]

3-(2-Diethylamino-propionamino)-rutaecarpine

Drug Info

[33]

3-(2-N-Piperidyl-propionamino)-rutaecarpine

Drug Info

[33]

3-(2-N-Pyrrolyl-acetamino)-rutaecarpine

Drug Info

[33]

3-(2-N-Pyrrolyl-propionamino)-rutaecarpine

Drug Info

[33]

3-(dimethylamino)phenyl phenylcarbamate

Drug Info

[11]

3-chlorophenyl 10H-phenothiazine-10-carboxylate

Drug Info

[30]

3-isopr-sal-cyclosal-d4TMP

Drug Info

[34]

3-methoxyphenyl 10H-phenothiazine-10-carboxylate

Drug Info

[30]

3-sal-cyclosal-d4TMP

Drug Info

[34]

3-[10-(benzylmethylamino)decyloxy]xanthen-9-one

Drug Info

[35]

3-[11-(benzylmethylamino)undecyloxy]xanthen-9-one

Drug Info

[35]

3-[12-(benzylmethylamino)dodecyloxy]xanthen-9-one

Drug Info

[35]

3-[3-(benzylmethylamino)propoxy]xanthen-9-one

Drug Info

[35]

3-[4-(benzylmethylamino)butoxy]xanthen-9-one

Drug Info

[35]

3-[5-(benzylmethylamino)pentyloxy]xanthen-9-one

Drug Info

[35]

3-[6-(benzylmethylamino)hexyloxy]xanthen-9-one

Drug Info

[35]

3-[7-(benzylmethylamino)-heptyloxy]xanthen-9-one

Drug Info

[35]

3-[8-(benzylmethylamino)octyloxy]xanthen-9-one

Drug Info

[35]

3-[9-(benzylmethylamino)nonyloxy]xanthen-9-one

Drug Info

[35]

4-chlorophenyl 10H-phenothiazine-10-carboxylate

Drug Info

[30]

4-ISOPROPYLPHENSERINE

Drug Info

[36], [37]

4-methoxyphenyl 10H-phenothiazine-10-carboxylate

Drug Info

[30]

4-[4-(benzyloxy)piperidino]butyl benzoate

Drug Info

[38]

4-[4-(benzyloxy)piperidino]butyl-3-chlorobenzoate

Drug Info

[38]

4-[4-(benzyloxy)piperidino]butyl-3-fluorobenzoate

Drug Info

[38]

4-[4-(benzyloxy)piperidino]butyl-4-chlorobenzoate

Drug Info

[38]

5-methyl-cyclosal-d4TMP

Drug Info

[34]

6-chlorotacrine hydrochloride

Drug Info

[39]

6-hydroxy-1,2,9-trimethyl-9H-beta-carbolin-2-ium

Drug Info

[40]

6-hydroxy-1,2-dimethyl-9H-beta-carbolin-2-ium

Drug Info

[40]

6-hydroxy-2-methyl-9H-beta-carbolin-2-ium

Drug Info

[40]

6-methoxy-1,2-dimethyl-9H-beta-carbolin-2-ium

Drug Info

[40]

7-Oxo-7H-dibenzo[de,g]quinoline

Drug Info

[41]

9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE

Drug Info

[20]

9-N-Phenylmethylamino-Tacrine

Drug Info

[29]

9-O-[2-(Phenylol-1-yloxy)ethyl]berberine bromide

Drug Info

[42]

9-O-[2-(Phenylol-1-yloxy)hexyl]berberine bromide

Drug Info

[42]

9-O-[3-(2-Pyridinoxyl)butyl]-berberine bromide

Drug Info

[25]

9-O-[3-(4-Nitro-phenoxyl)butyl]-berberine bromide

Drug Info

[25]

9-O-[3-(Phenylamino)propyl]-berberine bromide

Drug Info

[25]

9-O-[4-(Phenylol-1-yloxy)butyl]berberine bromide

Drug Info

[42]

100

9-O-[5-(Phenylol-1-yloxy)pentyl]berberine bromide

Drug Info

[42]

101

9-[5-(beta-Carboline-9-yl)pentyl]-beta-carboline

Drug Info

[31]

102

ACENAPHTHOQUINONE

Drug Info

[26]

103

Alpha-D-Mannose

Drug Info

[29]

104

Anthracen-10-yl(10H-phenothiazin-10-yl)methanone

Drug Info

[19]

105

AS-1397

Drug Info

[43]

106

BENZOQUINONE

Drug Info

[32]

107

Beta-D-Mannose

Drug Info

[29]

108

Bis-7-tacrine

Drug Info

[44]

109

Bis-cyclosal-d4TMP

Drug Info

[34]

110

Butanoic Acid

Drug Info

[29]

111

Butyrylthiocholine

Drug Info

[45]

112

CAPROCTAMINE

Drug Info

[46]

113

CHF-2819

Drug Info

[47]

114

CHLORANIL

Drug Info

[32]

115

Cyclopentyl 10H-phenothiazine-10-carboxylate

Drug Info

[30]

116

Cyclosal-d4TMP

Drug Info

[34]

117

DEMETHYLDEBROMOFLUSTRAMINE B

Drug Info

[17]

118

Diethylphosphono Group

Drug Info

[29]

119

Ethyl Dihydrogen Phosphate

Drug Info

[29]

120

ETHYL HYDROGEN DIETHYLAMIDOPHOSPHATE

Drug Info

[20]

121

Fucose

Drug Info

[29]

122

HALOXYSTEROL A

Drug Info

[21]

123

Haloxysterol C

Drug Info

[21]

124

Haloxysterol D

Drug Info

[21]

125

Huprine X

Drug Info

[48]

126

Huprine-Tacrine Heterodimer

Drug Info

[49]

127

Iso-OMPA

Drug Info

[50]

128

Isopropyl 10H-phenothiazine-10-carboxylate

Drug Info

[30]

129

Isosorbide-2-(benzylcarbamate)-5-benzoate

Drug Info

[50]

130

Isosorbide-2-(benzylcarbamate)-5-mononitrate

Drug Info

[50]

131

Isosorbide-2-(butylcarbamate)-5-mononitrate

Drug Info

[50]

132

Isosorbide-2-(cyclohexylcarbamate)-5-mononitrate

Drug Info

[50]

133

Isosorbide-2-(ethylcarbamate)-5-mononitrate

Drug Info

[50]

134

Isosorbide-2-(methylcarbamate)-5-benzoate

Drug Info

[50]

135

Isosorbide-2-(methylcarbamate)-5-mononitrate

Drug Info

[50]

136

Isosorbide-2-benzylcarbamate-5-(o-toluate)

Drug Info

[51]

137

Isosorbide-2-benzylcarbamate-5-acetate

Drug Info

[50]

138

Isosorbide-2-benzylcarbamate-5-cyclopentanoate

Drug Info

[50]

139

Isosorbide-2-benzylcarbamate-5-cyclopropanoate

Drug Info

[50]

140

Isosorbide-2-benzylcarbamate-5-isonicotinate

Drug Info

[50]

141

Isosorbide-2-benzylcarbamate-5-nicotinate

Drug Info

[50]

142

Isosorbide-2-benzylcarbamate-5-pentanoate

Drug Info

[50]

143

Isosorbide-2-benzylcarbamate-5-propionate

Drug Info

[50]

144

Isosorbide-2-benzylcarbamate-5-triflate

Drug Info

[50]

145

Isosorbide-di-(benzylcarbamate)

Drug Info

[52]

146

Isosorbide-di-(butylcarbamate)

Drug Info

[52]

147

Isosorbide-di-(ethylcarbamate)

Drug Info

[52]

148

Isosorbide-di-(propylcarbamate)

Drug Info

[52]

149

LIPOCRINE

Drug Info

[53]

150

M-tolyl 10H-phenothiazine-10-carboxylate

Drug Info

[30]

151

MEMOQUIN

Drug Info

[53]

152

Methyl 10H-phenothiazine-10-carboxylate

Drug Info

[30]

153

Methyl Phosphinic Acid

Drug Info

[29]

154

MF-8623

Drug Info

[36]

155

Monoisopropyl Ester Phosphonic Acid Group

Drug Info

[29]

156

Morpholino(1'H-phenothiazin-1'-yl)methanone

Drug Info

[18]

157

N,N'-(1',10'-decylene)-bis-(-)-nor-MEP

Drug Info

[10]

158

N,N'-(1',11'-undecydene)-bis-(-)-nor-MEP

Drug Info

[10]

159

N,N'-(1',12'-dodecydene)-bis-(-)-nor-MEP

Drug Info

[10]

160

N,N'-(1',3'-propylene)-bis-(-)-nor-MEP

Drug Info

[10]

161

N,N'-(1',4'-butylene)-bis-(-)-nor-MEP

Drug Info

[10]

162

N,N'-(1',5'-pentylene)-bis-(-)-nor-MEP

Drug Info

[10]

163

N,N'-(1',7'-heptylene)-bis-(-)-nor-MEP

Drug Info

[10]

164

N,N'-(1',9'-nonylene)-bis-(-)-nor-MEP

Drug Info

[10]

165

N,N-Diethyl-1'H-phenothiazine-1'-carboxamide

Drug Info

[18]

166

N,N-Diisopropyl-1'H-phenothiazine-1'-carboxamide

Drug Info

[18]

167

N,N-Dimethyl-1'H-phenothiazine-1'-carboxamide

Drug Info

[18]

168

N,N-Dipropyl-1'H-phenothiazine-1'-carboxamide

Drug Info

[18]

169

N-(Adamant-1-yl)-1'H-phenothiazine-1'-carboxamide

Drug Info

[18]

170

N-Benzyl-1'H-phenothiazine-1'-carboxamide

Drug Info

[18]

171

N-benzyl-2-thiomorpholinopyrimidin-4-amine

Drug Info

[44]

172

N-Cyclobutyl-1'H-phenothiazine-1'-carboxamide

Drug Info

[18]

173

N-Cyclohexyl-1'H-phenothiazine-1'-carboxamide

Drug Info

[18]

174

N-Cyclopentyl-1'H-phenothiazine-1'-carboxamide

Drug Info

[18]

175

N-Isopropyl-1'H-phenothiazine-1'-carboxamide

Drug Info

[18]

176

N-Methyl-1'H-phenothiazine-1'-carboxamide

Drug Info

[18]

177

N-n-heptyl-7-methoxytacrine hydrochloride

Drug Info

[54]

178

N-n-hexyl-7-methoxytacrine hydrochloride

Drug Info

[54]

179

N-n-nonyl-7-methoxytacrine hydrochloride

Drug Info

[54]

180

N-n-octyl-7-methoxytacrine hydrochloride

Drug Info

[54]

181

N-n-pentyl-7-methoxytacrine hydrochloride

Drug Info

[54]

182

N-Neopentyl-1'H-phenothiazine-1'-carboxamide

Drug Info

[18]

183

N-p-Tolyl-1'H-phenothiazine-1'-carboxamide

Drug Info

[18]

184

N-Phenyl-1'H-phenothiazine-1'-carboxamide

Drug Info

[18]

185

N-tert-Butyl-1'H-phenothiazine-1'-carboxamide

Drug Info

[18]

186

Naphthalen-1-yl 10H-phenothiazine-10-carboxylate

Drug Info

[30]

187

Naphthalen-1-yl(10H-phenothiazin-10-yl)methanone

Drug Info

[19]

188

Naphthalen-2-yl 10H-phenothiazine-10-carboxylate

Drug Info

[30]

189

Naphthalen-2-yl(10H-phenothiazin-10-yl)methanone

Drug Info

[19]

190

NOSTOCARBOLINE

Drug Info

[56]

191

NSC-23180

Drug Info

[26]

192

P-tolyl 10H-phenothiazine-10-carboxylate

Drug Info

[30]

193

Phenanthrene-9,10-dione

Drug Info

[26]

194

Tert-butyl 10H-phenothiazine-10-carboxylate

Drug Info

[30]

195

TOLSERINE

Drug Info

[12]

196

VAGANINE D

Drug Info

[57]

Modulator

[+] 5 Modulator drugs

JES-9501

Drug Info

[6]

Plasma derived human butyrylcholinesterase

Drug Info

[13]

Protexia

Drug Info

[14]

Non-PEGylated butyrylcholinesterase

Drug Info

[55]

Recombinant human butyrylcholinesterase

Drug Info

[55]

Cell-based Target Expression Variations

Top

Cell-based Target Expression Variations

Cell-based Target Expression Variations Info

Drug Binding Sites of Target

Top

Ligand Name: Tacrine

Ligand Info

Structure Description

Human butyrylcholinesterase in complex with tacrine

PDB:4BDS

Method

X-ray diffraction

Resolution

2.10 Å

Mutation

Yes

[58]

PDB Sequence

IIIATKNGKV

¹³

RGMQLTVFGG

²³

TVTAFLGIPY

³³

AQPPLGRLRF

⁴³

KKPQSLTKWS

⁵³

DIWNATKYAN

⁶³

SCCQNIDQSF

⁷³

PGFHGSEMWN

⁸³

PNTDLSEDCL

⁹³

YLNVWIPAPK

¹⁰³

PKNATVLIWI

¹¹³

YGGGFQTGTS

¹²³

SLHVYDGKFL

¹³³

ARVERVIVVS

¹⁴³

MNYRVGALGF

¹⁵³

LALPGNPEAP

¹⁶³

GNMGLFDQQL

¹⁷³

ALQWVQKNIA

¹⁸³

AFGGNPKSVT

¹⁹³

LFGESAGAAS

²⁰³

VSLHLLSPGS

²¹³

HSLFTRAILQ

²²³

SGSFNAPWAV

²³³

TSLYEARNRT

²⁴³

LNLAKLTGCS

²⁵³

RENETEIIKC

²⁶³

LRNKDPQEIL

²⁷³

LNEAFVVPYG

²⁸³

TPLSVNFGPT

²⁹³

VDGDFLTDMP

³⁰³

DILLELGQFK

³¹³

KTQILVGVNK

³²³

DEGTAFLVYG

³³³

APGFSKDNNS

³⁴³

IITRKEFQEG

³⁵³

LKIFFPGVSE

³⁶³

FGKESILFHY

³⁷³

TDWVQRPENY

³⁸⁵

REALGDVVGD

³⁹⁵

YNFICPALEF

⁴⁰⁵

TKKFSEWGNN

⁴¹⁵

AFFYYFEHRS

⁴²⁵

SKLPWPEWMG

⁴³⁵

VMHGYEIEFV

⁴⁴⁵

FGLPLERRDQ

⁴⁵⁵

YTKAEEILSR

⁴⁶⁵

SIVKRWANFA

⁴⁷⁵

KYGNPQETQN

⁴⁸⁵

QSTSWPVFKS

⁴⁹⁵

TEQKYLTLNT

⁵⁰⁵

ESTRIMTKLR

⁵¹⁵

AQQCRFWTSF

⁵²⁵

FPKV

Residue

Distance (Å)

ASP70

4.386

GLY78

4.290

SER79

4.694

TRP82

3.401

GLY115

3.976

GLY116

3.925

TYR128

4.335

GLU197

3.177

Residue

Distance (Å)

SER198

4.111

ALA328

3.766

TYR332

3.520

TRP430

3.523

MET437

3.907

HIS438

3.154

GLY439

3.908

TYR440

4.098

Ligand Name: Beta-L-fucose

Ligand Info

Structure Description

Human Butyrylcholinesterase complexed with N-Propargyliperidines

PDB:5LKR

Method

X-ray diffraction

Resolution

2.52 Å

Mutation

[59]

PDB Sequence

DIIIATKNGK

¹²

VRGMNLTVFG

²²

GTVTAFLGIP

³²

YAQPPLGRLR

⁴²

FKKPQSLTKW

⁵²

SDIWNATKYA

⁶²

NSCCQNIDQS

⁷²

FPGFHGSEMW

⁸²

NPNTDLSEDC

⁹²

LYLNVWIPAP

¹⁰²

KPKNATVLIW

¹¹²

IYGGGFQTGT

¹²²

SSLHVYDGKF

¹³²

LARVERVIVV

¹⁴²

SMNYRVGALG

¹⁵²

FLALPGNPEA

¹⁶²

PGNMGLFDQQ

¹⁷²

LALQWVQKNI

¹⁸²

AAFGGNPKSV

¹⁹²

TLFGESAGAA

²⁰²

SVSLHLLSPG

²¹²

SHSLFTRAIL

²²²

QSGSFNAPWA

²³²

VTSLYEARNR

²⁴²

TLNLAKLTGC

²⁵²

SRENETEIIK

²⁶²

CLRNKDPQEI

²⁷²

LLNEAFVVPY

²⁸²

GTPLSVNFGP

²⁹²

TVDGDFLTDM

³⁰²

PDILLELGQF

³¹²

KKTQILVGVN

³²²

KDEGTAFLVY

³³²

GAPGFSKDNN

³⁴²

SIITRKEFQE

³⁵²

GLKIFFPGVS

³⁶²

EFGKESILFH

³⁷²

YTDWVDDQRP

³⁸²

ENYREALGDV

³⁹²

VGDYNFICPA

⁴⁰²

LEFTKKFSEW

⁴¹²

GNNAFFYYFE

⁴²²

HRSSKLPWPE

⁴³²

WMGVMHGYEI

⁴⁴²

EFVFGLPLER

⁴⁵²

RDNYTKAEEI

⁴⁶²

LSRSIVKRWA

⁴⁷²

NFAKYGNPNE

⁴⁸²

TQNNSTSWPV

⁴⁹²

FKSTEQKYLT

⁵⁰²

LNTESTRIMT

⁵¹²

KLRAQQCRFW

⁵²²

TSFFPKVL

Residue

Distance (Å)

ASP3

4.148

ARG14

4.002

Residue

Distance (Å)

ASN57

4.765

Click to View More Binding Site Information of This Target and Ligand Pair

Click to View More Binding Site Information of This Target with Different Ligands

Different Human System Profiles of Target	Top
Human Similarity Proteins of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target. A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs (Brief Bioinform, 21: 649-662, 2020). Human Tissue Distribution of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues. The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects (Nat Rev Drug Discov, 20: 64-81, 2021). Biological Network Descriptors of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database. The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information (Front Pharmacol, 9, 1245, 2018; Curr Opin Struct Biol. 44:134-142, 2017). Human Similarity Proteins Human Tissue Distribution Biological Network Descriptors

Different Human System Profiles of Target

Top

Human Similarity Proteins of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.

A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs (Brief Bioinform, 21: 649-662, 2020).

Human Tissue Distribution of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues.

The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects (Nat Rev Drug Discov, 20: 64-81, 2021).

Biological Network Descriptors of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.

The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information (Front Pharmacol, 9, 1245, 2018; Curr Opin Struct Biol. 44:134-142, 2017).

Human Similarity Proteins

Human Tissue Distribution

Biological Network Descriptors

Protein Name	Pfam ID	Percentage of Identity (%)	E value
Arylacetamide deacetylase (AADAC)	PF07859	31.707 (39/123)	3.72E-05


Note: If a protein has TS (tissue specficity) scores at least in one tissue >= 2.5, this protein is called tissue-enriched (including tissue-enriched-but-not-specific and tissue-specific). In the plots, the vertical lines are at thresholds 2.5 and 4.

Degree	1	Degree centrality	1.07E-04	Betweenness centrality	0.00E+00
Closeness centrality	1.71E-01	Radiality	1.27E+01	Clustering coefficient	0.00E+00
Neighborhood connectivity	1.30E+01	Topological coefficient	1.00E+00	Eccentricity	13
Download	Click to Download the Full PPI Network of This Target

Chemical Structure based Activity Landscape of Target

Top

Drug Property Profile of Target

Top

(1) Molecular Weight (mw) based Drug Clustering

(2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering

(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering

(4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering

(5) Rotatable Bond Count (rotbonds) based Drug Clustering

(6) Topological Polar Surface Area (polararea) based Drug Clustering

"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five

Co-Targets

Top

Co-Targets

Co-Targets Info

Target Poor or Non Binders

Top

Target Poor or Non Binders

Target Poor or Non Binders Info

Target Affiliated Biological Pathways

Top

Panther Pathway

[+] 3 Panther Pathways

Muscarinic acetylcholine receptor 1 and 3 signaling pathway

Muscarinic acetylcholine receptor 2 and 4 signaling pathway

Nicotinic acetylcholine receptor signaling pathway

WikiPathways

[+] 1 WikiPathways

Irinotecan Pathway

Target-Related Models and Studies

Top

Target Validation

Target Validation Info

References

Top

REF 1

Synergistic effect of acidosis and succinylcholine-induced hyperkalemia in spinal cord transected rats. Acta Anaesthesiol Scand. 1984 Feb;28(1):87-90.

REF 2

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

REF 3

Pharmacology, clinical uses, and adverse effects of ceruletide, a cholecystokinetic agent. Pharmacotherapy. 1982 Jul-Aug;2(4):223-34.

REF 4

Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease. PLoS One. 2013;8(1):e54887.

REF 5

Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies. CNS Drug Rev. 2001 Winter;7(4):369-86.

REF 6

Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice. Eur J Pharmacol. 2001 Feb 16;413(2-3):221-5.

REF 7

ClinicalTrials.gov (NCT00333528) A Study of Plasma-Derived Human Butyrylcholinesterase Administered Intramuscularly. U.S. National Institutes of Health.

REF 8

ClinicalTrials.gov (NCT00744146) First Time in Human Study of Protexia. U.S. National Institutes of Health.

REF 9

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 10

Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.

REF 11

Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93.

REF 12

Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem. 2006 Apr 6;49(7):2174-85.

REF 13

Acetylcholinesterase-Fc Fusion Protein (AChE-Fc): A Novel Potential Organophosphate Bioscavenger with Extended Plasma Half-Life. Bioconjug Chem. 2015 Aug 19;26(8):1753-8.

REF 14

In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact. 2005 Dec 15;157-158:363-5.

REF 15

A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.

REF 16

Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.

REF 17

Synthesis and biological evaluation of (-)- and (+)-debromoflustramine B and its analogues as selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Sep 11;51(17):5271-84.

REF 18

Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244.

REF 19

Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78.

REF 20

The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

REF 21

Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80.

REF 22

Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely... J Med Chem. 2008 Jun 12;51(11):3154-70.

REF 23

Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for My... Bioorg Med Chem Lett. 2010 Mar 1;20(5):1763-6.

REF 24

Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17.

REF 25

Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84.

REF 26

Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34.

REF 27

Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.

REF 28

Homobivalent quinazolinimines as novel nanomolar inhibitors of cholinesterases with dirigible selectivity toward butyrylcholinesterase. J Med Chem. 2006 Sep 7;49(18):5411-3.

REF 29

How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

REF 30

Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12.

REF 31

Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.

REF 32

Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.

REF 33

Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23.

REF 34

Bis-cycloSal-d4T-monophosphates: drugs that deliver two molecules of bioactive nucleotides. J Med Chem. 2007 Mar 22;50(6):1335-46.

REF 35

Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85.

REF 36

A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin. 2001;17(3):159-65.

REF 37

Design, synthesis, evaluation and QSAR analysis of N(1)-substituted norcymserine derivatives as selective butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1718-20.

REF 38

Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abe... Bioorg Med Chem. 2007 Oct 15;15(20):6596-607.

REF 39

Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds. J Med Chem. 2009 Sep 10;52(17):5365-79.

REF 40

6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3.

REF 41

Synthesis, biological evaluation and molecular modeling of oxoisoaporphine and oxoaporphine derivatives as new dual inhibitors of acetylcholinester... Eur J Med Chem. 2009 Jun;44(6):2523-32.

REF 42

Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1244-51.

REF 43

Novel heterobivalent tacrine derivatives as cholinesterase inhibitors with notable selectivity toward butyrylcholinesterase. J Med Chem. 2006 Dec 14;49(25):7540-4.

REF 44

Design, synthesis and evaluation of 2,4-disubstituted pyrimidines as cholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3606-9.

REF 45

DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.

REF 46

Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inne... J Med Chem. 2008 Nov 27;51(22):7308-12.

REF 47

Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine. J Med Chem. 2005 Feb 24;48(4):986-94.

REF 48

Discovery of huperzine A-tacrine hybrids as potent inhibitors of human cholinesterases targeting their midgorge recognition sites. J Med Chem. 2006 Jun 1;49(11):3421-5.

REF 49

Synthesis and pharmacological evaluation of huprine-tacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors. J Med Chem. 2005 Mar 24;48(6):1701-4.

REF 50

Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.

REF 51

Isosorbide-2-benzyl carbamate-5-salicylate, a peripheral anionic site binding subnanomolar selective butyrylcholinesterase inhibitor. J Med Chem. 2010 Feb 11;53(3):1190-9.

REF 52

Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability. Bioorg Med Chem. 2010 Feb;18(3):1045-53.

REF 53

Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks. J Med Chem. 2009 Dec 10;52(23):7883-6.

REF 54

Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5.

REF 55

URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2471).

REF 56

Nostocarboline: isolation and synthesis of a new cholinesterase inhibitor from Nostoc 78-12A. J Nat Prod. 2005 Dec;68(12):1793-5.

REF 57

Steroidal alkaloids from the leaves of Sarcococca coriacea of Nepalese origin. J Nat Prod. 2001 Jun;64(6):842-4.

REF 58

Crystal structures of human cholinesterases in complex with huprine W and tacrine: elements of specificity for anti-Alzheimer's drugs targeting acetyl- and butyryl-cholinesterase. Biochem J. 2013 Aug 1;453(3):393-9.

REF 59

N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents. Bioorg Med Chem. 2017 Jan 15;25(2):633-645.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Prof. Yuzong CHEN

Prof. Feng ZHU